Brief: Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026
07/01/2026 14:47
Jan 7 (Reuters) - Enliven Therapeutics Inc ELVN.O: ENLIVEN THERAPEUTICS INC - CONTINUES TO PREPARE FOR PHASE 3 TRIAL INITIATION IN 2026 AND THE COMMERCIALIZATION OF ELVN-001 Source text: ID:nPn1pmSzCa Further company coverage: ELVN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses